Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aristo Bio-Tech and Lifescience's enterprise value is ₹1,090 Mil.
Aristo Bio-Tech and Lifescience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ₹101 Mil. Therefore, Aristo Bio-Tech and Lifescience's EV-to-EBITDA for today is 10.83.
The historical rank and industry rank for Aristo Bio-Tech and Lifescience's EV-to-EBITDA or its related term are showing as below:
NSE:ARISTO's EV-to-EBITDA is not ranked *
in the Agriculture industry.
Industry Median: 9.12 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aristo Bio-Tech and Lifescience (NSE:ARISTO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aristo Bio-Tech and Lifescience's PE Ratio (TTM) for today is calculated as:
Aristo Bio-Tech and Lifescience's share price for today is ₹112.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aristo Bio-Tech and Lifescience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹5.970.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aristo Bio-Tech and Lifescience EV-to-EBITDA Chart
For the Agricultural Inputs subindustry, Aristo Bio-Tech and Lifescience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aristo Bio-Tech and Lifescience EV-to-EBITDA vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Aristo Bio-Tech and Lifescience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aristo Bio-Tech and Lifescience's EV-to-EBITDA falls into.
Aristo Bio-Tech and Lifescience's current Enterprise Value is ₹1,090 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aristo Bio-Tech and Lifescience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ₹101 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a EV-to-EBITDA of 10.83 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aristo Bio-Tech and Lifescience.
Is Aristo Bio-Tech and Lifescience's EV-to-EBITDA too high?
Aristo Bio-Tech and Lifescience's current EV-to-EBITDA is 10.83. The Agriculture industry median EV-to-EBITDA is 9.12. Aristo Bio-Tech and Lifescience's value of 10.83 is 18.8% above this industry median. Overall, Aristo Bio-Tech and Lifescience has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Aristo Bio-Tech and Lifescience's EV-to-EBITDA compare to CTVA and CF?
Aristo Bio-Tech and Lifescience's EV-to-EBITDA of 10.83 can be compared against companies in the Agriculture industry. The industry median EV-to-EBITDA is 9.12. Aristo Bio-Tech and Lifescience's value of 10.83 is 18.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for an Agriculture company?
The median EV-to-EBITDA among Agriculture companies is 9.12, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aristo Bio-Tech and Lifescience's current EV-to-EBITDA of 10.83 is 18.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aristo Bio-Tech and Lifescience. For the Agriculture industry, the median EV-to-EBITDA is 9.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aristo Bio-Tech and Lifescience's current EV-to-EBITDA is 10.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aristo Bio-Tech and Lifescience stock overvalued right now?
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a current EV-to-EBITDA of 10.83. The current EV-to-EBITDA is 10.83 and 18.8% above the Agriculture industry median of 9.12. Aristo Bio-Tech and Lifescience's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aristo Bio-Tech and Lifescience (NSE:ARISTO), the current EV-to-EBITDA is 10.83 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aristo Bio-Tech and Lifescience Ltd is an agrochemical company. It is mainly engaged in the manufacturing, formulation, supplying, packaging and job work services of various pesticides. The company exports products like Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals.
59GF Score
Get the complete analysis for NSE:ARISTO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ARISTO has been successfully added to your 
